Molecular Partners? strategic partner Allergan announced today that EMA has validated the marketing authorisation application for abicipar
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
Zurich-Schlieren, Switzerland, August 6, 2019.?Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin? therapies*, today announced that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) of its strategic partner Allergan for abicipar, a novel DARPin? therapy for the treatment of nAMD. If approved, abicipar is expected to be the first anti-VEGF therapy to sustain vision gains on a true fixed 12-week dosing interval. The validation of the MAA confirms that the submission by the EMA is sufficiently complete to begin the formal review process.
http://investors.molecularpartners.com/financial-calendar-and-events/
*DARPin??is a registered trademark owned by Molecular Partners AG
Financial Calendar
August 27, 2019 | Publication of Half-year Results 2019 (unaudited) |
October 31, 2019 | Interim Management Statement Q3 2019 |
December 12, 2019 | R&D Day in New York |